An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:

June 12, 2018

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question. The recent results from the TAILORx clinical trial evaluating Oncotype DX are important for patients and their oncologists, but they also…

Read more

Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients

May 29, 2018

New data from the I-SPY 2 trial highlights residual cancer burden as a prognostic indicator for long-term outcomes in patients pre-selected using MammaPrint NBRST trial reports three-year patient outcomes showing that the use of MammaPrint and BluePrint testing in the neoadjuvant setting can help indicate improved outcomes and survival in patients with a specific subtype…

Read more

Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia

May 24, 2018

Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for early breast cancer IRVINE, CA AND AMSTERDAM, NETHERLANDS – 24 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics…

Read more

Agendia’s MammaPrint and BluePrint Breast Cancer Tests Selected by Unicancer for French Patients

May 15, 2018

IRVINE, CA, AMSTERDAM, NETHERLANDS – 15 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer…

Read more